M. Baekelandt

Oslo University Hospital — Norway

Medicine · Health Sciences

25h-index1.9kcitations77works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(36), Endometrial and Cervical Cancer Treatments(14), Intraperitoneal and Appendiceal Malignancies(8), Cancer-related Molecular Pathways(7), Cancer, Lipids, and Metabolism(6)

Publications77 total

Limitations of tissue microarrays compared with whole tissue sections in survival analysis
Oncology Letters·2010· 49 citedOpen Access
A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients
Journal of Clinical Oncology·2009· 1 cited
A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients
Journal of Clinical Oncology·2009· 2 cited
A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin versus paclitaxel-carboplatin as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients
Journal of Clinical Oncology·2009· 8 cited
Endometrial carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Annals of Oncology·2009· 90 citedOpen Access
Large mammographic opacity due to hamartoma.
PubMed·2008
Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Journal of Clinical Oncology·2008· 154 citedOpen Access
Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: A NSGO study
Journal of Clinical Oncology·2008· 13 cited
A Nordic Society of Gynecological Oncology (NSGO) multicenter, non-randomized, phase II study of docetaxel and carboplatin as second-line chemotherapy in patients with first elapse of platinum-sensitive epithelial ovarian, peritoneal or fallopian tube cancer
University of Southern Denmark Research Portal (University of Southern Denmark)·2008
MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells
Diagnostic Cytopathology·2007· 45 cited
The Clinical Importance of Ki-67, p16, p14, and p57 Expression in Patients With Advanced Ovarian Carcinoma
International Journal of Gynecological Pathology·2007· 51 cited
The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma
Gynecologic Oncology·2006· 38 cited
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma
Gynecologic Oncology·2006· 41 cited
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in theTP53 gene on survival in patients with advanced ovarian carcinoma
Human Mutation·2006
Fibrolamellar hepatocellular carcinoma in a 65-year-old woman: CT features.
PubMed·2005· 12 cited
First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival
International Journal of Gynecological Cancer·2005· 7 cited
Risk grouping in stage IB squamous cell cervical carcinoma
Gynecologic Oncology·2005· 71 cited
Markers of apoptosis in stage IB squamous cervical carcinoma
Journal of Clinical Pathology·2005· 6 citedOpen Access
357 The Potential Prognostic and Predictive Significance of Cell Cycle-Related Proteins Ki-67, P16, P14 and P57 in Advanced Ovarian Cancer
International Journal of Gynecological Cancer·2004Open Access
424 Prognostic Factors in Early Stage Squamous Cell Cervical Carcinoma
International Journal of Gynecological Cancer·2004
page 1 of 4Next →

Frequent Co-authors

Gunnar B. Kristensen(20), Ruth Holm(11), Claes G. Tropé(7), Claes G. Tropé(5), Vera M. Abeler(4), Jahn M. Nesland(4), Stefaan Gryspeerdt(4), B Van Holsbeeck(4), Anne Jorunn Nesbakken(3), P. Buytaert(3), J. M. Nesland(3), Gregg Van de Putte(3), A. Kathrine Lie(3), Gustav Lehne(3), Ben Davidson(3), J. Kærn(3), Ignace Vergote(3), J. Herrstedt(3), Jens Huober(3), Frank Priou(3)